Literature DB >> 19667249

Xanthine oxidoreductase depletion induces renal interstitial fibrosis through aberrant lipid and purine accumulation in renal tubules.

Toshio Ohtsubo1, Kiyoshi Matsumura, Kanae Sakagami, Koji Fujii, Kazuhiko Tsuruya, Hideko Noguchi, Ilsa I Rovira, Toren Finkel, Mitsuo Iida.   

Abstract

Xanthine oxidoreductase (XOR) is an enzyme responsible for purine degradation, reactive oxygen species production, and adipogenesis. XOR gene-disrupted (XOR(-/-)) mice demonstrate renal failure and early death within several months. The aim of this study was to elucidate the mechanism of renal damage in XOR(-/-) mice and to determine the physiological role of XOR in the kidney. Histological analysis revealed that renal tubular damage in XOR(-/-) mice was accompanied by deposition of crystals and lipid-rich substances. Triglyceride content in renal homogenates was significantly increased in XOR(-/-) mice. The level of lipogenesis-related gene expression was comparable in XOR(+/+) and XOR(-/-) mice, whereas the expression of adipogenesis-related gene expression was significantly elevated in XOR(-/-) mice. Urinary excretions of xanthine and hypoxanthine were markedly elevated in XOR(-/-) mice. Immunohistochemical analysis, Western blotting, and real time RT-PCR revealed that various markers of fibrosis, inflammation, ischemia, and oxidative stress were increased in XOR(-/-) mice. Finally, we demonstrate that primary renal epithelial cells from XOR(-/-) mice are more readily transformed to myofibroblasts, which is a marker of increased epithelial mesenchymal transition. These results suggest that XOR gene disruption induced the depletion of uric acid and the accumulation of triglyceride-rich substances, xanthine, and hypoxanthine in the renal tubules. We believe that these changes contribute to a complex cellular milieu characterized by inflammation, tissue hypoxia, and reactive oxygen species production, ultimately resulting in renal failure through increased renal interstitial fibrosis.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19667249      PMCID: PMC3773720          DOI: 10.1161/HYPERTENSIONAHA.109.135152

Source DB:  PubMed          Journal:  Hypertension        ISSN: 0194-911X            Impact factor:   10.190


  38 in total

Review 1.  Peroxisomal purine metabolism.

Authors:  A V Yeldandi; R Chu; J Pan; Y Zhu; N Usuda
Journal:  Ann N Y Acad Sci       Date:  1996-12-27       Impact factor: 5.691

2.  Identification of two mutations in human xanthine dehydrogenase gene responsible for classical type I xanthinuria.

Authors:  K Ichida; Y Amaya; N Kamatani; T Nishino; T Hosoya; O Sakai
Journal:  J Clin Invest       Date:  1997-05-15       Impact factor: 14.808

3.  The peroxynitrite scavenger uric acid prevents inflammatory cell invasion into the central nervous system in experimental allergic encephalomyelitis through maintenance of blood-central nervous system barrier integrity.

Authors:  R B Kean; S V Spitsin; T Mikheeva; G S Scott; D C Hooper
Journal:  J Immunol       Date:  2000-12-01       Impact factor: 5.422

4.  Renal abnormalities and an altered inflammatory response in mice lacking cyclooxygenase II.

Authors:  J E Dinchuk; B D Car; R J Focht; J J Johnston; B D Jaffee; M B Covington; N R Contel; V M Eng; R J Collins; P M Czerniak
Journal:  Nature       Date:  1995-11-23       Impact factor: 49.962

5.  Prostaglandin synthase 2 gene disruption causes severe renal pathology in the mouse.

Authors:  S G Morham; R Langenbach; C D Loftin; H F Tiano; N Vouloumanos; J C Jennette; J F Mahler; K D Kluckman; A Ledford; C A Lee; O Smithies
Journal:  Cell       Date:  1995-11-03       Impact factor: 41.582

6.  Hereditary xanthinuria. Evidence for enhanced hypoxanthine salvage.

Authors:  F A Mateos; J G Puig; M L Jiménez; I H Fox
Journal:  J Clin Invest       Date:  1987-03       Impact factor: 14.808

7.  Role of altered renal lipid metabolism in the development of renal injury induced by a high-fat diet.

Authors:  Shinji Kume; Takashi Uzu; Shin-ichi Araki; Toshiro Sugimoto; Keiji Isshiki; Masami Chin-Kanasaki; Masayoshi Sakaguchi; Naoto Kubota; Yasuo Terauchi; Takashi Kadowaki; Masakazu Haneda; Atsunori Kashiwagi; Daisuke Koya
Journal:  J Am Soc Nephrol       Date:  2007-09-12       Impact factor: 10.121

8.  Xanthine dehydrogenase and xanthine oxidase activity and gene expression in renal epithelial cells. Cytokine and steroid regulation.

Authors:  K D Pfeffer; T P Huecksteadt; J R Hoidal
Journal:  J Immunol       Date:  1994-08-15       Impact factor: 5.422

9.  Superoxide radicals in feline intestinal ischemia.

Authors:  D N Granger; G Rutili; J M McCord
Journal:  Gastroenterology       Date:  1981-07       Impact factor: 22.682

10.  Apoptosis in metanephric development.

Authors:  C Koseki; D Herzlinger; Q al-Awqati
Journal:  J Cell Biol       Date:  1992-12       Impact factor: 10.539

View more
  28 in total

1.  Xanthine oxidoreductase mediates membrane docking of milk-fat droplets but is not essential for apocrine lipid secretion.

Authors:  Jenifer Monks; Monika Dzieciatkowska; Elise S Bales; David J Orlicky; Richard M Wright; James L McManaman
Journal:  J Physiol       Date:  2016-08-03       Impact factor: 5.182

2.  Peroxisome proliferator-activated receptor A/G reprogrammes metabolism associated with lipid accumulation in macrophages.

Authors:  Guozhu Ye; Han Gao; Yi Lin; Dongxiao Ding; Xu Liao; Han Zhang; Yulang Chi; Sijun Dong
Journal:  Metabolomics       Date:  2019-03-04       Impact factor: 4.290

Review 3.  Renal lipid metabolism and lipotoxicity.

Authors:  Ion Alexandru Bobulescu
Journal:  Curr Opin Nephrol Hypertens       Date:  2010-07       Impact factor: 2.894

Review 4.  Uric acid as a target of therapy in CKD.

Authors:  Diana I Jalal; Michel Chonchol; Wei Chen; Giovanni Targher
Journal:  Am J Kidney Dis       Date:  2012-10-09       Impact factor: 8.860

5.  Mouse model for molybdenum cofactor deficiency type B recapitulates the phenotype observed in molybdenum cofactor deficient patients.

Authors:  Joanna Jakubiczka-Smorag; Jose Angel Santamaria-Araujo; Imke Metz; Avadh Kumar; Samy Hakroush; Wolfgang Brueck; Guenter Schwarz; Peter Burfeind; Jochen Reiss; Lukasz Smorag
Journal:  Hum Genet       Date:  2016-05-02       Impact factor: 4.132

6.  Safety and Efficacy of Benzbromarone and Febuxostat in Hyperuricemia Patients with Chronic Kidney Disease: A Prospective Pilot Study.

Authors:  Haibo Yu; Xinying Liu; Yaxiang Song; Jiafen Cheng; Hui Bao; Ling Qin; Xuan Zhou; Ling Wang; Ai Peng
Journal:  Clin Exp Nephrol       Date:  2018-05-14       Impact factor: 2.801

7.  Uric acid secretion from adipose tissue and its increase in obesity.

Authors:  Yu Tsushima; Hitoshi Nishizawa; Yoshihiro Tochino; Hideaki Nakatsuji; Ryohei Sekimoto; Hirofumi Nagao; Takashi Shirakura; Kenta Kato; Keiichiro Imaizumi; Hiroyuki Takahashi; Mizuho Tamura; Norikazu Maeda; Tohru Funahashi; Iichiro Shimomura
Journal:  J Biol Chem       Date:  2013-08-02       Impact factor: 5.157

Review 8.  Chemistry meets biology in colitis-associated carcinogenesis.

Authors:  A Mangerich; P C Dedon; J G Fox; S R Tannenbaum; G N Wogan
Journal:  Free Radic Res       Date:  2013-10-04

9.  Effects of uric acid dysregulation on the kidney.

Authors:  Lashodya V Dissanayake; Denisha R Spires; Oleg Palygin; Alexander Staruschenko
Journal:  Am J Physiol Renal Physiol       Date:  2020-03-30

10.  A mouse model of early-onset renal failure due to a xanthine dehydrogenase nonsense mutation.

Authors:  Sian E Piret; Christopher T Esapa; Caroline M Gorvin; Rosie Head; Nellie Y Loh; Olivier Devuyst; Gethin Thomas; Steve D M Brown; Matthew Brown; Peter Croucher; Roger Cox; Rajesh V Thakker
Journal:  PLoS One       Date:  2012-09-14       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.